- 30 minutes ago
- 7 min read
Medically reviewed by ChinaCureLink Team
ChinaCureLink helps international patients access this pilot treatment in China by connecting you with 2–3 hospitals that match your specific case and arranging an online consultation before you fly—so you can understand potential eligibility and next steps before committing to travel.
Knee osteoarthritis stem cell treatment using umbilical cord-derived mesenchymal stem cells (UC-MSCs) is listed as an innovative treatment option for patients with moderate-to-severe knee osteoarthritis. The treatment involves a local injection into the knee joint cavity. Individual suitability must be determined by an attending physician.
Key Takeaways
UC-MSC therapy uses mesenchymal stem cells derived from umbilical cord tissue and delivers them by local injection into the knee joint cavity.
The supplied listing describes the treatment for moderate-to-severe knee osteoarthritis.
The reference price is 36,500 yuan per dose; final pricing should be confirmed during hospital consultation.
Eligibility is determined by physician assessment, including evaluation of imaging, joint condition, and overall health.
The treatment is listed among Lecheng's first batch of approved biomedical new technology listings, with a 2025 registration year and low-risk classification according to the supplied source.
The listing does not establish that the treatment is a cure or guarantee a particular outcome.
Table of Contents |
Understanding Umbilical Cord MSC Therapy for Knee Osteoarthritis
Umbilical cord MSC therapy for knee osteoarthritis uses mesenchymal stem cells derived from umbilical cord tissue and delivers them by local injection into the knee joint cavity.
MSC stands for mesenchymal stem cell. The treatment described in the supplied source is specifically an injection-based approach using UC-MSCs for patients with moderate-to-severe knee osteoarthritis.
The Treatment Approach in Plain Language
The treatment involves delivering umbilical cord-derived MSCs directly into the knee joint cavity. This should not be confused with every type of treatment marketed generally as "stem cell therapy," because different products can use different cell sources, administration methods, and protocols.
The Patient Population Described in the Source
The supplied listing identifies moderate-to-severe knee osteoarthritis as the relevant condition. However, the diagnosis alone does not establish eligibility. A physician must assess the patient's individual medical situation.
How the UC-MSC Treatment Works
At a high level, the therapy delivers umbilical cord-derived mesenchymal stem cells locally into the knee joint cavity.
The supplied material confirms the cell source and administration method but does not provide enough information to establish a detailed biological mechanism. It also does not establish specific outcomes such as cartilage regeneration, pain reduction, improved mobility, or avoidance of knee replacement.
Patients should therefore discuss the proposed mechanism, available clinical evidence, expected outcomes, and uncertainties directly with the treating physician.
Eligibility and Patient Selection
The listed treatment is intended for patients with moderate-to-severe knee osteoarthritis whose suitability is confirmed by an attending physician after clinical evaluation.
Eligibility factor | Source-supported requirement | |
Condition | Knee osteoarthritis | |
Severity | Moderate to severe | |
Imaging | Reviewed during evaluation | |
Joint condition | Assessed by attending physician | |
Overall health | Considered during evaluation | |
Final suitability | Determined by physician | |
Self-diagnosis | Not appropriate |
Clinical Evaluation Before Treatment
The physician evaluates relevant imaging, the condition of the knee joint, and the patient's overall health. The supplied material does not establish specific age requirements, exclusion criteria, imaging thresholds, or previous-treatment requirements.
Knee Osteoarthritis Stem Cell Treatment in China and the Lecheng Access Pathway
The supplied therapy is listed among Lecheng's first batch of approved biomedical new technology listings, with a 2025 registration year and low-risk classification according to the source.
This wording is important for international patients. A listing through a pilot-zone pathway should not automatically be interpreted as nationwide approval or as evidence that the treatment is a proven cure for knee osteoarthritis.
Access is through the relevant pilot-zone medical pathway and remains subject to physician evaluation and current availability.
What the Pilot-Zone Status Means for International Patients
Pilot-zone availability can provide a pathway for selected innovative medical technologies. However, access status and clinical evidence are separate questions.
Before traveling, patients should confirm the current treatment availability, eligibility requirements, regulatory status, and evidence with the relevant medical team.
Cost and What It Covers
The supplied reference price is 36,500 yuan per dose. Final pricing should be confirmed during hospital consultation.
The supplied material does not provide a verified USD conversion or establish that this price represents the patient's total medical-tourism cost.
Costs to Confirm Before Travel
Patients should confirm whether additional charges apply for:
Medical consultation and evaluation
Imaging or diagnostic assessments
Treatment-related hospital services
Translation or coordination
Follow-up care
Travel and accommodation
No additional amounts should be assumed without confirmation from the medical provider.
How This Approach Compares With Other Knee OA Treatment Options
UC-MSC injection is an innovative/pilot treatment approach for selected patients. It should not automatically be considered superior to established knee osteoarthritis management options.
Option | General role | What patients should consider |
Conventional/non-surgical care | Established management | Discuss established options with a physician |
Surgical treatment | Option for selected advanced disease | Requires individualized clinical assessment |
UC-MSC injection | Innovative/pilot treatment | Review eligibility, evidence, risks, and access |
Other regenerative approaches | Different treatment modalities | Evidence and protocols may differ |
Comparative claims about effectiveness or safety require independent clinical evidence.
How ChinaCureLink Can Help International Patient to Get Access to This Treatment
ChinaCureLink can help international patients explore the treatment pathway while leaving medical decisions to qualified physicians.
Case and Eligibility Assessment
ChinaCureLink can collect relevant medical information and help determine whether the case is appropriate for physician review.
Matching Patients With 2–3 Suitable Partner Hospitals
ChinaCureLink can identify 2–3 hospitals that may match the patient's specific case, rather than presenting one hospital as the default destination.
Online Consultation Before Travel
Patients can arrange an online consultation before committing to international travel. This allows the medical team to review the case and discuss potential eligibility and next steps.
Coordination After a Hospital Match
Depending on the services available, support may include communication and translation assistance, appointment coordination, travel logistics, treatment coordination, and follow-up support.
ChinaCureLink does not guarantee eligibility, treatment acceptance, clinical outcomes, or access.
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
Is knee osteoarthritis stem cell treatment available in China?
Yes. The supplied listing describes UC-MSC injection treatment for moderate-to-severe knee osteoarthritis through the relevant Lecheng pilot-zone pathway. Current availability and individual eligibility should be confirmed with the medical provider.
How does umbilical cord MSC injection treatment work for knee osteoarthritis?
The treatment uses mesenchymal stem cells derived from umbilical cord tissue and delivers them locally into the knee joint cavity. The supplied source does not establish a specific biological mechanism or guaranteed outcome.
Who may be eligible for stem cell treatment for knee osteoarthritis?
The listed treatment is intended for patients with moderate-to-severe knee osteoarthritis. Final suitability depends on physician evaluation of the patient's imaging, joint condition, overall health, and other relevant clinical information.
How much does knee osteoarthritis stem cell treatment cost in China?
The supplied reference price is 36,500 yuan per dose. Patients should confirm the current price and what the quoted amount includes during hospital consultation.
Is umbilical cord MSC therapy a cure for knee osteoarthritis?
The supplied material does not establish that UC-MSC therapy is a cure. Patients should discuss the available evidence, potential risks, expected outcomes, and alternatives with a qualified physician.
How can international patients access knee osteoarthritis stem cell treatment in China?
International patients can begin with medical record review and physician evaluation. ChinaCureLink can help match patients with 2–3 potentially suitable hospitals and arrange an online consultation before travel.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
References and Further Reading
Boao Lecheng International Medical Tourism Pilot Zone — Hainan Provincial Government: Official background on the pilot zone, its medical-access framework, international-patient services, and medical innovation policies. Boao Lecheng International Medical Tourism Pilot Zone — Hainan Provincial Government
Boao Lecheng International Medical Tourism Pilot Zone — Hainan Free Trade Port: Official information on the pilot zone's medical-technology access policies and healthcare services. Boao Lecheng International Medical Tourism Pilot Zone — Hainan Free Trade Port
Implementation Plan for Supporting the Development of the Boao Lecheng International Medical Tourism Pilot Zone — National Development and Reform Commission: Official Chinese government policy information concerning the development and regulatory framework of the pilot zone. National Development and Reform Commission — Boao Lecheng Implementation Plan
Lecheng International Medical Tourism Service Center — Hainan Provincial Government: Official information on the international-patient service infrastructure established in Lecheng in 2026. Lecheng International Medical Tourism Service Center
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
Comments